Both parks have their own piece of The Wizarding World of Harry Potter, making a tough choice for Harry Potter fans. Many or all of the products on this page are from partners who compensate us ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday ...

Subscribe today. Don’t get me wrong, I love a good campsite. But sometimes after a big day of adventure, I crave the comfort and ease of a great hotel with a friendly staff, farm-to-table meals ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

Coincidentally, several of my friends and adventure buddies were also rethinking their relationship with alcohol last year, for various reasons. As I began trying to be more intentional about when ...